| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
All-Male Panels and Gender Diversity of Issue Panels and Plenary Sessions at ISPOR Europe
|
Bouvy, Jacoline C.
|
|
2019
|
3 |
3 |
p. 419-422
|
artikel
|
| 2 |
All Male Panels and Other Diversity Considerations for ISPOR
|
Devlin, Nancy J.
|
|
2019
|
3 |
3 |
p. 423-426
|
artikel
|
| 3 |
A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
|
Walton, M. J.
|
|
2019
|
3 |
3 |
p. 403-410
|
artikel
|
| 4 |
Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis
|
McCausland, Kristen L.
|
|
2019
|
3 |
3 |
p. 367-375
|
artikel
|
| 5 |
Correction to: Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations
|
Shen, Jing
|
|
2019
|
3 |
3 |
p. 427
|
artikel
|
| 6 |
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
|
Bullement, Ash
|
|
2019
|
3 |
3 |
p. 377-390
|
artikel
|
| 7 |
Cost of Treatment of Valvular Heart Disease at a Tertiary Hospital in North India: Policy Implications
|
Prinja, Shankar
|
|
2019
|
3 |
3 |
p. 391-402
|
artikel
|
| 8 |
Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials
|
Porter, Joshua K.
|
|
2018
|
3 |
3 |
p. 411-417
|
artikel
|
| 9 |
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
|
Quon, Peter L.
|
|
2019
|
3 |
3 |
p. 321-331
|
artikel
|
| 10 |
Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study
|
Entrenas Costa, Luis Manuel
|
|
2019
|
3 |
3 |
p. 333-342
|
artikel
|
| 11 |
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Fleeman, Nigel
|
|
2019
|
3 |
3 |
p. 293-302
|
artikel
|
| 12 |
Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group
|
Keeping, Stuart
|
|
2019
|
3 |
3 |
p. 343-350
|
artikel
|
| 13 |
Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing
|
Vogler, Sabine
|
|
2019
|
3 |
3 |
p. 303-309
|
artikel
|
| 14 |
Extending Life in Duchenne Muscular Dystrophy: Implications for Appraisals of Cost-Effectiveness
|
Landfeldt, Erik
|
|
2018
|
3 |
3 |
p. 279-280
|
artikel
|
| 15 |
Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study
|
Sebastian, Shaji
|
|
2019
|
3 |
3 |
p. 359-365
|
artikel
|
| 16 |
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
|
Lee, Dawn
|
|
2018
|
3 |
3 |
p. 351-358
|
artikel
|
| 17 |
The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method
|
Moradi, Najme
|
|
2019
|
3 |
3 |
p. 311-319
|
artikel
|
| 18 |
Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK
|
Yang, Yaling
|
|
2018
|
3 |
3 |
p. 281-291
|
artikel
|
Tijdschrift beschrijving